Technical Analysis for SNPX - Synaptogenix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.41 | -3.22% | -0.15 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -3.22% | |
NR7 | Range Contraction | -3.22% | |
Narrow Range Bar | Range Contraction | -3.22% | |
Inside Day | Range Contraction | -3.22% | |
20 DMA Resistance | Bearish | -3.44% |
Alert | Time |
---|---|
Possible NR7 | about 15 hours ago |
60 Minute Opening Range Breakout | about 18 hours ago |
10 DMA Resistance | about 18 hours ago |
Fell Below Previous Day's Low | about 19 hours ago |
Down 2 % | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Stroke Multiple Sclerosis Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 47.0 |
52 Week Low | 3.5275 |
Average Volume | 49,492 |
200-Day Moving Average | 8.40 |
50-Day Moving Average | 4.76 |
20-Day Moving Average | 4.66 |
10-Day Moving Average | 4.55 |
Average True Range | 0.52 |
RSI (14) | 44.75 |
ADX | 30.04 |
+DI | 18.30 |
-DI | 12.77 |
Chandelier Exit (Long, 3 ATRs) | 4.65 |
Chandelier Exit (Short, 3 ATRs) | 5.44 |
Upper Bollinger Bands | 5.14 |
Lower Bollinger Band | 4.18 |
Percent B (%b) | 0.24 |
BandWidth | 20.71 |
MACD Line | -0.09 |
MACD Signal Line | -0.07 |
MACD Histogram | -0.0233 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.69 | ||||
Resistance 3 (R3) | 4.72 | 4.66 | 4.65 | ||
Resistance 2 (R2) | 4.66 | 4.59 | 4.65 | 4.63 | |
Resistance 1 (R1) | 4.54 | 4.55 | 4.51 | 4.51 | 4.62 |
Pivot Point | 4.48 | 4.48 | 4.46 | 4.46 | 4.48 |
Support 1 (S1) | 4.35 | 4.40 | 4.32 | 4.32 | 4.21 |
Support 2 (S2) | 4.29 | 4.36 | 4.27 | 4.19 | |
Support 3 (S3) | 4.16 | 4.29 | 4.18 | ||
Support 4 (S4) | 4.13 |